High Rates of Viral Suppression After Long-Term Entecavir Treatment of Asian Pat

StephenW

Clin Gastroenterol Hepatol. 2012 Apr 1. [Epub ahead of print]
High Rates of Viral Suppression After Long-Term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B.Pan CQ, Tong M, Kowdley KV, Hu KQ, Chang TT, Lai CL, Yoon SK, Lee SS, Cohen D, Tang H, Tsai N.
SourceDivision of Liver Diseases, Mount Sinai School of Medicine, New York, New York.

Abstract
There are limited data on the effects of long-term entecavir therapy in Asian patients with chronic hepatitis B (CHB). We performed a post hoc analysis of 94 Asian hepatitis B e antigen-positive (HBeAg+), nucleos(t)ide analog-naive patients who received 5 years of therapy with entecavir (up to 2 years in study ETV-022 and the remainder in study ETV-901). Among patients completing week 240, 95% (63 of 66) had levels of hepatitis B virus DNA <300 copies/mL, and 76% (50 of 66) had normalized levels of alanine aminotransferase. In addition to patients who achieved a serologic response during ETV-022, another 40% (26 of 65) achieved HBeAg loss, and 18% (12 of 65) underwent HBeAg seroconversion after 5 years of therapy with entecavir. No resistance to entecavir was detected, and the safety profile was consistent with previous reports. The long-term efficacy and safety of entecavir are therefore comparable between Asians and the overall population of HBeAg+ patients with CHB.

StephenW

临床胃肠肝胆病杂志。 2012年4月1。 [出处提前打印]
经过长期的亚洲与B型肝炎e抗原阳性慢性乙型肝炎患者的恩替卡韦治疗抑制病毒的高利率
重庆泛塘中号，Kowdley千伏，胡克勤，张TT，赖才，尹SK，李SS，科恩ð，唐Ĥ，蔡N.
源

肝脏疾病，医药，纽约，纽约的西奈山医学院的分工。
抽象

有长期恩替卡韦治疗慢性乙型肝炎（CHB）的亚洲患者的影响是有限的数据。我们的表现194亚洲肝炎事后分析乙e抗原阳性（HBeAg阳性+），核苷（T）IDE模拟，天真的病人谁接受恩替卡韦（最多2个多年研究教育电视-022和的其余部分在5年的治疗研究ETV-901）。在完成一周240例，有95％（6663）乙肝病毒DNA水平<300拷贝/毫升，76％（6650），谷丙转氨酶的正常水平。此外ETV-022期间取得的血清学反应的患者，另外40％（6526）实现HBeAg消失，18％（6512）接受恩替卡韦治疗5年后HBeAg血清转换。没有恩替卡韦的耐药性检测，安全性是与以前的报告一致。恩替卡韦的长期疗效和安全，因此，亚洲人和总人口+慢性乙型肝炎患者的HBeAg之间是可比(类似)。